首页 > 最新文献

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia最新文献

英文 中文
Use of a rapid detection test for extended-spectrum beta-lactamase from direct blood culture: an antimicrobial stewardship tool in a tertiary hospital in Spain.
Montserrat Rodríguez-Ayala, Juana Cacho-Calvo, Emilio Cendejas-Bueno

Introduction: Bacteremia caused by Gram-negative bacilli places a substantial burden on healthcare systems, mainly due to antibiotic resistance and delays in administering appropriate antimicrobial treatment (AT). The aim of this study was to describe the implementation of a rapid detection test (RDT) for CTX-M Extended Spectrum Beta-Lactamase-producing Enterobacterales (ESBL-PE) bacteremia as a tool for Antimicrobial Stewardship (AMS) in a tertiary hospital in Spain.

Material and methods: A cross-sectional study was conducted on blood culture (BC) samples from adult patients (≥18 years) admitted to a tertiary hospital in Spain (January 2021-February 2024). BCs with confirmed Enterobacterales identification were included. An RDT was used to detect CTX-M ESBL from direct BC. The results were reported to the AMS team. Data from electronic medical records and our laboratory information system were analyzed to explore the utility of implementing an RDT as an AMS tool.

Results: A total of 250 BCs from 250 patients were included. Empiric antimicrobial treatment (EAT) had not been prescribed in 41/250 (16.4%) patients, but was appropriately initiated in 33/250 (13.2%) after notification of the RDT results. Among those already receiving EAT (209/250, 83.6%), inappropriate and appropriate actions in AT were observed in 18/250 (7.2%) and 191/250 (76.4%) patients, respectively. By the time routine AST results were available, 241 (96.4%) patients had received appropriate treatment.

Conclusions: This study demonstrated the real-world application of an RDT to detect CTX-M ESBL directly from BC in a tertiary hospital. Early reporting of CTX-M ESBL status in Enterobacterales bacteremia enabled physicians and AMS teams to optimize AT.

{"title":"Use of a rapid detection test for extended-spectrum beta-lactamase from direct blood culture: an antimicrobial stewardship tool in a tertiary hospital in Spain.","authors":"Montserrat Rodríguez-Ayala, Juana Cacho-Calvo, Emilio Cendejas-Bueno","doi":"10.37201/req/108.2024","DOIUrl":"https://doi.org/10.37201/req/108.2024","url":null,"abstract":"<p><strong>Introduction: </strong>Bacteremia caused by Gram-negative bacilli places a substantial burden on healthcare systems, mainly due to antibiotic resistance and delays in administering appropriate antimicrobial treatment (AT). The aim of this study was to describe the implementation of a rapid detection test (RDT) for CTX-M Extended Spectrum Beta-Lactamase-producing <i>Enterobacterales</i> (ESBL-PE) bacteremia as a tool for Antimicrobial Stewardship (AMS) in a tertiary hospital in Spain.</p><p><strong>Material and methods: </strong>A cross-sectional study was conducted on blood culture (BC) samples from adult patients (≥18 years) admitted to a tertiary hospital in Spain (January 2021-February 2024). BCs with confirmed <i>Enterobacterales</i> identification were included. An RDT was used to detect CTX-M ESBL from direct BC. The results were reported to the AMS team. Data from electronic medical records and our laboratory information system were analyzed to explore the utility of implementing an RDT as an AMS tool.</p><p><strong>Results: </strong>A total of 250 BCs from 250 patients were included. Empiric antimicrobial treatment (EAT) had not been prescribed in 41/250 (16.4%) patients, but was appropriately initiated in 33/250 (13.2%) after notification of the RDT results. Among those already receiving EAT (209/250, 83.6%), inappropriate and appropriate actions in AT were observed in 18/250 (7.2%) and 191/250 (76.4%) patients, respectively. By the time routine AST results were available, 241 (96.4%) patients had received appropriate treatment.</p><p><strong>Conclusions: </strong>This study demonstrated the real-world application of an RDT to detect CTX-M ESBL directly from BC in a tertiary hospital. Early reporting of CTX-M ESBL status in <i>Enterobacterales</i> bacteremia enabled physicians and AMS teams to optimize AT.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":"38 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort. 阿根廷艾滋病毒感染者接受比特拉韦/恩曲他滨/替诺福韦-阿拉非酰胺固定剂量联合疗法的有效性、安全性和患者报告结果:BICTARG 队列。
Pub Date : 2025-02-01 Epub Date: 2024-11-20 DOI: 10.37201/req/080.2024
D Cecchini, M Brizuela, M S Seleme, M V Mingrone, G Copertari, B Bacelar, R Mauas, E Bottaro, I Cassetti

Objective: Real-world data on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) fixed-dose combination from resource-constrained settings like Latin America are limited.

Methods: We conducted an observational retrospective cohort study of treatment-naive (TN, n=315) and treatment-experienced (TE, n= 2356) people living with HIV prescribed BIC/FTC/TAF in Argentina from 10/2019 to 12/2021, with 24 and 48-week follow-up data analyzed for virological suppression, persistence, safety, and metabolic parameters. Patient-reported outcomes were assessed via across-sectional online survey.

Results: Baseline characteristics: median age 45 years, 72.2% male, 99.6% Hispanic/Latino ethnicity. Treatment per sistence at 48 weeks was 99.3% (TN) and 99.5% (TE). Virological suppression rates (<200/<50 copies/mL) at 24 weeks were 97.4/88% (TN) and 99/97% (TE). At 48 weeks were 100/92% (TN) and 99/97% (TE). In the TE group, triglycerides decreased with no other lipid changes. In TN, mild total/LDL/HDL cholesterol increases occurred. eGFR mildly decreased in both groups. The online survey (n=536) showed 91.5% reported no medication concerns. Median quality of life scores were 90 (TN) and 88 (TE). Most reported no self-care, activity, mobility, pain/discomfort, or anxiety/depression issues.

Conclusions: BIC/FTC/TAF demonstrated high persistence, safety, virological efficacy, and favorable metabolic profile over 48 weeks. The cross-sectional survey indicated high treatment satisfaction and good quality of life in this cohort from Argentina.

目的:在拉丁美洲等资源有限的地区,有关比特拉韦/恩曲他滨/替诺福韦-阿拉非那胺(BIC/FTC/TAF)固定剂量复方制剂的真实世界数据十分有限:我们开展了一项观察性回顾性队列研究,研究对象为2019年10月至2021年12月期间在阿根廷接受BIC/FTC/TAF处方治疗的非治疗性(TN,n=315)和有治疗经验(TE,n=2356)的HIV感染者,并对24周和48周的随访数据进行了病毒学抑制、持续性、安全性和代谢参数分析。患者报告的结果通过跨部门在线调查进行评估:基线特征:中位年龄 45 岁,72.2% 为男性,99.6% 为西班牙/拉丁美洲裔。48周的治疗持续率分别为99.3%(TN)和99.5%(TE)。病毒抑制率(结论:BIC/FTC/TAF 在 48 周内表现出较高的持续性、安全性、病毒学疗效和良好的代谢特征。横断面调查显示,阿根廷的这批患者对治疗的满意度很高,生活质量也很好。
{"title":"Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort.","authors":"D Cecchini, M Brizuela, M S Seleme, M V Mingrone, G Copertari, B Bacelar, R Mauas, E Bottaro, I Cassetti","doi":"10.37201/req/080.2024","DOIUrl":"10.37201/req/080.2024","url":null,"abstract":"<p><strong>Objective: </strong>Real-world data on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) fixed-dose combination from resource-constrained settings like Latin America are limited.</p><p><strong>Methods: </strong>We conducted an observational retrospective cohort study of treatment-naive (TN, n=315) and treatment-experienced (TE, n= 2356) people living with HIV prescribed BIC/FTC/TAF in Argentina from 10/2019 to 12/2021, with 24 and 48-week follow-up data analyzed for virological suppression, persistence, safety, and metabolic parameters. Patient-reported outcomes were assessed via across-sectional online survey.</p><p><strong>Results: </strong>Baseline characteristics: median age 45 years, 72.2% male, 99.6% Hispanic/Latino ethnicity. Treatment per sistence at 48 weeks was 99.3% (TN) and 99.5% (TE). Virological suppression rates (<200/<50 copies/mL) at 24 weeks were 97.4/88% (TN) and 99/97% (TE). At 48 weeks were 100/92% (TN) and 99/97% (TE). In the TE group, triglycerides decreased with no other lipid changes. In TN, mild total/LDL/HDL cholesterol increases occurred. eGFR mildly decreased in both groups. The online survey (n=536) showed 91.5% reported no medication concerns. Median quality of life scores were 90 (TN) and 88 (TE). Most reported no self-care, activity, mobility, pain/discomfort, or anxiety/depression issues.</p><p><strong>Conclusions: </strong>BIC/FTC/TAF demonstrated high persistence, safety, virological efficacy, and favorable metabolic profile over 48 weeks. The cross-sectional survey indicated high treatment satisfaction and good quality of life in this cohort from Argentina.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"40-47"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and prognostic value of time to positivity in blood cultures. An opinion paper. 血液培养阳性时间的诊断和预后价值。意见书。
Pub Date : 2025-02-01 Epub Date: 2024-11-19 DOI: 10.37201/req/094.2024
P Maffezzoli, M Kestler, A Burillo, S Corcione, F G De Rosa, P Muñoz, E Bouza

Time to positivity (TTP) refers to the duration required for a microbiological culture test to indicate a positive result, marking the onset of detectable bacterial or fungal growth in the sample. Numerous variables, including patient characteristics, infection source, former antimicrobial therapy, blood sample volume, and sample transportation time can influence the value of TTP. Several studies have been conducted on bloodstream infections, whereas studies on the clinical significance of yeast TTP are quite limited in the literature. Furthermore, many studies are retrospective and have a small sample size. In this opinion paper, we have formulated some questions and attempted to provide answers based on the available literature and our perspective. The objective of this opinion paper is to summarise current knowledge based on the literature, aiming to offer a critical perspective, particularly on aspects with weaker evidence, which could guide future studies in this area. We believe that TTP of blood cultures appears to exhibit considerable potential and may prove to be a valuable tool in clinical practice for estimating patient mortality risk and guiding antimicrobial therapy choices. Topics discussed include the diagnostic and prognostic role of TTP in Gram-positive and Gram-negative bacteremias and in candidemias, and the significance of differential time to positivity (DTTP). In summary, our opinion is that, based on the available literature, it is not possible to determine whether TTP provides prognostic information, particularly concerning candidemia. Therefore, clinical decisions cannot be systematically based on this parameter.

阳性时间(TTP)是指微生物培养检测显示阳性结果所需的时间,标志着样本中开始出现可检测到的细菌或真菌生长。患者特征、感染源、曾接受的抗菌治疗、血液样本量和样本运送时间等众多变量都会影响 TTP 的值。关于血流感染的研究已有数项,而关于酵母菌 TTP 临床意义的研究在文献中却非常有限。此外,许多研究都是回顾性的,样本量较小。在本意见书中,我们提出了一些问题,并试图根据现有文献和我们的观点给出答案。本意见书的目的是根据文献总结当前的知识,旨在提供一个批判性的视角,尤其是在证据较弱的方面,从而为该领域未来的研究提供指导。我们认为,血培养 TTP 似乎具有相当大的潜力,在临床实践中可能会被证明是估算患者死亡风险和指导抗菌治疗选择的重要工具。讨论的主题包括 TTP 在革兰氏阳性菌、革兰氏阴性菌和念珠菌病中的诊断和预后作用,以及差异阳性时间 (DTTP) 的意义。总之,我们认为,根据现有文献,无法确定 TTP 是否能提供预后信息,尤其是在念珠菌病方面。因此,临床决策不能系统地以该参数为基础。
{"title":"Diagnostic and prognostic value of time to positivity in blood cultures. An opinion paper.","authors":"P Maffezzoli, M Kestler, A Burillo, S Corcione, F G De Rosa, P Muñoz, E Bouza","doi":"10.37201/req/094.2024","DOIUrl":"10.37201/req/094.2024","url":null,"abstract":"<p><p>Time to positivity (TTP) refers to the duration required for a microbiological culture test to indicate a positive result, marking the onset of detectable bacterial or fungal growth in the sample. Numerous variables, including patient characteristics, infection source, former antimicrobial therapy, blood sample volume, and sample transportation time can influence the value of TTP. Several studies have been conducted on bloodstream infections, whereas studies on the clinical significance of yeast TTP are quite limited in the literature. Furthermore, many studies are retrospective and have a small sample size. In this opinion paper, we have formulated some questions and attempted to provide answers based on the available literature and our perspective. The objective of this opinion paper is to summarise current knowledge based on the literature, aiming to offer a critical perspective, particularly on aspects with weaker evidence, which could guide future studies in this area. We believe that TTP of blood cultures appears to exhibit considerable potential and may prove to be a valuable tool in clinical practice for estimating patient mortality risk and guiding antimicrobial therapy choices. Topics discussed include the diagnostic and prognostic role of TTP in Gram-positive and Gram-negative bacteremias and in candidemias, and the significance of differential time to positivity (DTTP). In summary, our opinion is that, based on the available literature, it is not possible to determine whether TTP provides prognostic information, particularly concerning candidemia. Therefore, clinical decisions cannot be systematically based on this parameter.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"8-20"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of AmpliSens® HCV genotype-FRT-g-1-6 PCR kit with Abbott® Real Time HCV genotype II assay for hepatitis C virus genotyping. AmpliSens® HCV 基因型-FRT-g-1-6 PCR 试剂盒与雅培® Real Time HCV 基因型 II 检测法在丙型肝炎病毒基因分型方面的比较。
Pub Date : 2025-02-01 Epub Date: 2024-11-13 DOI: 10.37201/req/059.2024
A Maldonado-Barrueco, C Sanz-González, A Avellón, D Montero-Vega, C Vidales-Míguez, L Carisimo-Benavente, I Falces-Romero
{"title":"Comparison of AmpliSens® HCV genotype-FRT-g-1-6 PCR kit with Abbott® Real Time HCV genotype II assay for hepatitis C virus genotyping.","authors":"A Maldonado-Barrueco, C Sanz-González, A Avellón, D Montero-Vega, C Vidales-Míguez, L Carisimo-Benavente, I Falces-Romero","doi":"10.37201/req/059.2024","DOIUrl":"10.37201/req/059.2024","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"59-61"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142634677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Epidemiological and clinical management aspects related to urinary tract infections diagnosed in the emergency department in elderly patients in Spain: Results of the EDEN-36 study]. [西班牙老年患者在急诊科确诊的尿路感染相关流行病学和临床管理问题:EDEN-36研究结果]。
Pub Date : 2025-02-01 Epub Date: 2024-11-14 DOI: 10.37201/req/066.2024
O J Salmerón Béliz, E Pérez-Fernández, O Miró, S Aguiló, G Burillo-Putze, A Alquézar-Arbé, C Fernández-Alonso, J Jacob, F J Montero Pérez, A Melcon Villalibre, S Cuerpo Cardeñosa, L Serrano Lázaro, M Caballero Martínez, E Muñoz Soler, I Bajo Fernández, A I Castuera Gil, R Hernando González, A Carbó-Jordá, I Cabrera Rodrigo, B Gros Bañeres, C Romero Carrete, R Ríos Gallardo, A Cortés Soler, E González Nespereira, A García García, J R Oliva Ramos, L Hinojosa Diaz, J González Del Castillo

Objective: To estimate the incidence of urinary tract infections (UTI) in elderly patients in Spanish emergency departments (ED), the need for hospitalization, diagnostic confirmation in hospitalized patients, adverse events and the predictive capacity of several biomarkers.

Methods: In this a posteriori substudy of a generic study of reasons for ED visits in elderly patients, we included patients aged ≥65 years seen in 52 Spanish EDs for 1 week, selecting those diagnosed with UTI. As adverse events, in-hospital and 30-day mortality and combined adverse event (death or hospitalization) at 30 days post-discharge were collected. Relative risks (RR) were calculated. The predictive capacity of 10 variables and 6 biomarkers was investigated.

Results: A total of 25,375 patients were included, 1058 with UTI (annual incidence: 24.7 per 1000 inhabitants aged ≥65 years and year, 95%CI: 24.5-24.9). A total of 36.5% were hospitalized, and in 80% the diagnosis of UTI was confirmed at discharge. Overall 30-day mortality was 5.4% and in-hospital mortality was 3.4%. Functional dependence was associated with both events (RR:2.91;1.18-7.17 and RR:12.61;1.47-108.11, respectively), as was having a CRP greater than 100 mg/L (RR:2.24;1.17-4.30 and RR:3.21;1.37-7.51, respectively). The combined post-high event occurred in 10.6%, and was associated with functional dependence (RR:2.05;1.04-4.06). CRP and hemoglobin had significant value in predicting 30-day post-discharge mortality or hospitalization.

Conclusions: UTI is a frequent diagnosis in elderly patients consulting in the ED. Functional dependence is the best factor associated with adverse events. The biomarkers analyzed do not have a good predictive capacity.

目的估计西班牙急诊科(ED)中老年患者尿路感染(UTI)的发病率、住院需求、住院患者的诊断确认、不良事件以及几种生物标志物的预测能力:在这项关于老年患者急诊室就诊原因的一般性研究的后继研究中,我们纳入了在西班牙 52 家急诊室就诊 1 周的年龄≥65 岁的患者,并选择了确诊为UTI 的患者。作为不良事件,我们收集了院内和 30 天死亡率以及出院后 30 天的综合不良事件(死亡或住院)。计算了相对风险(RR)。研究了 10 个变量和 6 个生物标志物的预测能力:共纳入 25,375 名患者,其中 1058 人患有 UTI(年发病率:每 1000 名年龄≥65 岁的居民中 24.7 例,95%CI:24.5-24.9 例)。共有 36.5% 的患者住院治疗,其中 80% 的患者在出院时确诊为尿毒症。30天的总死亡率为5.4%,院内死亡率为3.4%。功能依赖与这两起事件有关(RR:2.91;1.18-7.17 和 RR:12.61;1.47-108.11),CRP 超过 100 mg/L 也与这两起事件有关(RR:2.24;1.17-4.30 和 RR:3.21;1.37-7.51)。10.6%的患者合并有高血压后遗症,且与功能依赖有关(RR:2.05;1.04-4.06)。CRP和血红蛋白在预测出院后30天的死亡率或住院率方面具有重要价值:结论:尿毒症是老年急诊患者的常见诊断。结论:尿毒症是急诊室就诊的老年患者的常见诊断,功能依赖是与不良事件相关的最佳因素。所分析的生物标志物没有很好的预测能力。
{"title":"[Epidemiological and clinical management aspects related to urinary tract infections diagnosed in the emergency department in elderly patients in Spain: Results of the EDEN-36 study].","authors":"O J Salmerón Béliz, E Pérez-Fernández, O Miró, S Aguiló, G Burillo-Putze, A Alquézar-Arbé, C Fernández-Alonso, J Jacob, F J Montero Pérez, A Melcon Villalibre, S Cuerpo Cardeñosa, L Serrano Lázaro, M Caballero Martínez, E Muñoz Soler, I Bajo Fernández, A I Castuera Gil, R Hernando González, A Carbó-Jordá, I Cabrera Rodrigo, B Gros Bañeres, C Romero Carrete, R Ríos Gallardo, A Cortés Soler, E González Nespereira, A García García, J R Oliva Ramos, L Hinojosa Diaz, J González Del Castillo","doi":"10.37201/req/066.2024","DOIUrl":"10.37201/req/066.2024","url":null,"abstract":"<p><strong>Objective: </strong>To estimate the incidence of urinary tract infections (UTI) in elderly patients in Spanish emergency departments (ED), the need for hospitalization, diagnostic confirmation in hospitalized patients, adverse events and the predictive capacity of several biomarkers.</p><p><strong>Methods: </strong>In this a posteriori substudy of a generic study of reasons for ED visits in elderly patients, we included patients aged ≥65 years seen in 52 Spanish EDs for 1 week, selecting those diagnosed with UTI. As adverse events, in-hospital and 30-day mortality and combined adverse event (death or hospitalization) at 30 days post-discharge were collected. Relative risks (RR) were calculated. The predictive capacity of 10 variables and 6 biomarkers was investigated.</p><p><strong>Results: </strong>A total of 25,375 patients were included, 1058 with UTI (annual incidence: 24.7 per 1000 inhabitants aged ≥65 years and year, 95%CI: 24.5-24.9). A total of 36.5% were hospitalized, and in 80% the diagnosis of UTI was confirmed at discharge. Overall 30-day mortality was 5.4% and in-hospital mortality was 3.4%. Functional dependence was associated with both events (RR:2.91;1.18-7.17 and RR:12.61;1.47-108.11, respectively), as was having a CRP greater than 100 mg/L (RR:2.24;1.17-4.30 and RR:3.21;1.37-7.51, respectively). The combined post-high event occurred in 10.6%, and was associated with functional dependence (RR:2.05;1.04-4.06). CRP and hemoglobin had significant value in predicting 30-day post-discharge mortality or hospitalization.</p><p><strong>Conclusions: </strong>UTI is a frequent diagnosis in elderly patients consulting in the ED. Functional dependence is the best factor associated with adverse events. The biomarkers analyzed do not have a good predictive capacity.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"28-39"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142634195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maintained susceptibility to fosfomycin in extra-hospitalary urinary isolates of Escherichia coli. Strong association of fosfomycin resistance with age and ESBL production. 院外尿路分离的大肠杆菌对磷霉素保持敏感性。磷霉素耐药性与年龄和ESBL产生密切相关。
Pub Date : 2025-02-01 Epub Date: 2024-12-20 DOI: 10.37201/req/016.2024
E Hidalgo, A González-Torralba, J Ramón, J I Alós

Objective: Escherichia coli is isolated in most of uncomplicated community-acquired urinary tract infections (UTI) and fosfomycin is one of the treatments of choice. We analyzed the evolution of fosfomycin resistance in extrahospitalary E. coli urinary isolates and whether age and extended spectrum beta-lactamase (ESBL) production were associated to antibiotic resistance.

Methods: A retrospective descriptive study was conducted from January 2017 to December 2022 including E. coli isolates from extrahospitalary urine samples.

Results: The susceptibility to fosfomycin remained above 95% during the study period. ESBL production and age above 80 years were significantly associated with increased fosfomycin resistance. We also analyzed the consumption of fosfomycin and it remained stable, although it was higher in the population >65 years.

Conclusions: Greater resistance is observed in ESBL-producing strains and in patients over 65 years of age. A stable consumption of fosfomycin is associated with low resistance percentages maintained over the time.

目的:在大多数无并发症的社区获得性尿路感染(UTI)中分离出大肠杆菌,磷霉素是首选的治疗方法之一。我们分析了院外大肠杆菌尿分离株对磷霉素耐药性的演变,以及年龄和广谱β -内酰胺酶(ESBL)的产生是否与抗生素耐药性有关。方法:2017年1月至2022年12月进行回顾性描述性研究,包括从院外尿液样本中分离出的大肠杆菌。结果:研究期间对磷霉素的敏感性保持在95%以上。ESBL的产生和年龄在80岁以上与磷霉素耐药性的增加显著相关。我们还分析了磷霉素的消耗量,它保持稳定,尽管它在65岁以上的人群中较高。结论:在产esbl菌株和65岁以上患者中观察到更大的耐药性。磷霉素的稳定消耗与长期维持的低耐药百分比有关。
{"title":"Maintained susceptibility to fosfomycin in extra-hospitalary urinary isolates of Escherichia coli. Strong association of fosfomycin resistance with age and ESBL production.","authors":"E Hidalgo, A González-Torralba, J Ramón, J I Alós","doi":"10.37201/req/016.2024","DOIUrl":"10.37201/req/016.2024","url":null,"abstract":"<p><strong>Objective: </strong>Escherichia coli is isolated in most of uncomplicated community-acquired urinary tract infections (UTI) and fosfomycin is one of the treatments of choice. We analyzed the evolution of fosfomycin resistance in extrahospitalary E. coli urinary isolates and whether age and extended spectrum beta-lactamase (ESBL) production were associated to antibiotic resistance.</p><p><strong>Methods: </strong>A retrospective descriptive study was conducted from January 2017 to December 2022 including E. coli isolates from extrahospitalary urine samples.</p><p><strong>Results: </strong>The susceptibility to fosfomycin remained above 95% during the study period. ESBL production and age above 80 years were significantly associated with increased fosfomycin resistance. We also analyzed the consumption of fosfomycin and it remained stable, although it was higher in the population >65 years.</p><p><strong>Conclusions: </strong>Greater resistance is observed in ESBL-producing strains and in patients over 65 years of age. A stable consumption of fosfomycin is associated with low resistance percentages maintained over the time.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"55-58"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A simple cellulitis after pruning the garden? A case report]. [修剪花园后的单纯蜂窝织炎? 一份病例报告]。
Pub Date : 2025-02-01 Epub Date: 2024-11-25 DOI: 10.37201/req/081.2024
A Uribarri, M Lorente-Escudero, C Vázquez, L Lozano-Vicario
{"title":"[A simple cellulitis after pruning the garden? A case report].","authors":"A Uribarri, M Lorente-Escudero, C Vázquez, L Lozano-Vicario","doi":"10.37201/req/081.2024","DOIUrl":"10.37201/req/081.2024","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"64-66"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142712255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Bacteremia due to strict anaerobes]. [严格厌氧菌引起的菌血症]。
Pub Date : 2025-02-01 Epub Date: 2024-11-18 DOI: 10.37201/req/063.2024
C Piña Delgado, M Bolaños Rivero, M C Carmona Tello, C J Ramírez Estupiñán, P M Hernández Cabrera, I de Miguel Martínez

Objective: Anaerobic bacteremia represents 0.5-12% of all bacteremias and its mortality is high, ranging from 25-44%. The aim was to know our data to compare them with existing data and demonstrate the importance of actively searching for these microorganisms in blood culture samples.

Methods: A retrospective descriptive study in which the medical records of patients with significant episodes of anaerobic bacteremia were reviewed over a period of 8 years (2014-2022).

Results: A total of 59,898 blood cultures were processed, of which 10,451 were positive (17%). An anaerobic microorganism was identified in 209 patients. Anaerobic bacteremia accounted for 2.11% of the total number of positive blood cultures. The mean age was 63.55 years (17-96), 66% of whom were men. The origin was community in 63.64%, of nosocomial origin in 15.31% and associated with health care in 17.70%. The focus of infection was the abdominal (39.23%), followed by the respiratory (13.88%) and skin and soft tissues (13.39%). The most frequent comorbidities were: arterial hypertension (49.76%), dyslipidemia (29.67%), neoplasia (26.32%) and diabetes (26.32%). The main species isolated were the group Bacteroides spp. (44.50%) (n=93) highlighting Bacteroides group fragilis (n=65), followed by Clostridium spp. (20%) (n=42) highlighting Clostridium perfringens (n=30). The clinical evolution was good in 67.46%. The mean length of stay was 27.8 days and was associated with 20% mortality.

Conclusions: Bacteremias due to anaerobes represented 2.11% of the total number of true bacteremias, so we consider the active search for these microorganisms to be appropriate.

目的:厌氧菌血症占所有菌血症的 0.5-12%,死亡率很高,在 25-44% 之间。我们的目的是了解我们的数据,将其与现有数据进行比较,并证明在血液培养样本中积极寻找这些微生物的重要性:方法:一项回顾性描述性研究,回顾了8年间(2014-2022年)发生重大厌氧菌血症患者的病历:共处理了 59898 份血液培养,其中 10451 份呈阳性(17%)。在 209 名患者中发现了厌氧微生物。厌氧菌血症占血液培养阳性总数的 2.11%。患者平均年龄为 63.55 岁(17-96 岁),其中 66% 为男性。63.64%的感染源于社区,15.31%源于院内,17.70%与医疗保健有关。感染的重点是腹部(39.23%),其次是呼吸道(13.88%)以及皮肤和软组织(13.39%)。最常见的合并症是:动脉高血压(49.76%)、血脂异常(29.67%)、肿瘤(26.32%)和糖尿病(26.32%)。分离出的主要菌种是脆弱拟杆菌属(44.50%)(93 人),其中脆弱拟杆菌属占 65 人,其次是梭状芽孢杆菌属(20%)(42 人),其中产气荚膜梭状芽孢杆菌占 30 人。67.46%的患者临床表现良好。平均住院时间为27.8天,死亡率为20%:厌氧菌引起的菌血症占真正菌血症总数的 2.11%,因此我们认为积极寻找这些微生物是适当的。
{"title":"[Bacteremia due to strict anaerobes].","authors":"C Piña Delgado, M Bolaños Rivero, M C Carmona Tello, C J Ramírez Estupiñán, P M Hernández Cabrera, I de Miguel Martínez","doi":"10.37201/req/063.2024","DOIUrl":"10.37201/req/063.2024","url":null,"abstract":"<p><strong>Objective: </strong>Anaerobic bacteremia represents 0.5-12% of all bacteremias and its mortality is high, ranging from 25-44%. The aim was to know our data to compare them with existing data and demonstrate the importance of actively searching for these microorganisms in blood culture samples.</p><p><strong>Methods: </strong>A retrospective descriptive study in which the medical records of patients with significant episodes of anaerobic bacteremia were reviewed over a period of 8 years (2014-2022).</p><p><strong>Results: </strong>A total of 59,898 blood cultures were processed, of which 10,451 were positive (17%). An anaerobic microorganism was identified in 209 patients. Anaerobic bacteremia accounted for 2.11% of the total number of positive blood cultures. The mean age was 63.55 years (17-96), 66% of whom were men. The origin was community in 63.64%, of nosocomial origin in 15.31% and associated with health care in 17.70%. The focus of infection was the abdominal (39.23%), followed by the respiratory (13.88%) and skin and soft tissues (13.39%). The most frequent comorbidities were: arterial hypertension (49.76%), dyslipidemia (29.67%), neoplasia (26.32%) and diabetes (26.32%). The main species isolated were the group Bacteroides spp. (44.50%) (n=93) highlighting Bacteroides group fragilis (n=65), followed by Clostridium spp. (20%) (n=42) highlighting Clostridium perfringens (n=30). The clinical evolution was good in 67.46%. The mean length of stay was 27.8 days and was associated with 20% mortality.</p><p><strong>Conclusions: </strong>Bacteremias due to anaerobes represented 2.11% of the total number of true bacteremias, so we consider the active search for these microorganisms to be appropriate.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"21-27"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strengths and weaknesses of computerized clinical decision support systems: insights from a digital control center (C3 COVID-19) for early and personalized treatment for COVID-19. 计算机化临床决策支持系统的优缺点:数字控制中心(C3 COVID-19)对 COVID-19 早期个性化治疗的启示。
Pub Date : 2025-02-01 Epub Date: 2024-10-29 DOI: 10.37201/req/088.2024
T F Aiello, C Teijon-Lumbreras, A Gallardo-Pizarro, P Monzó-Gallo, A Martinez-Urrea, G Cuervo, A Del Rio, M Hernández-Meneses, L Morata, J Mensa, A Soriano, C Garcia-Vidal

Clinical Decision Support Systems (CDSS) are computer-based tools that leverage the analysis of large volumes of health data to assist healthcare professionals in making clinical decisions, whether preventive, diagnostic, or therapeutic. This review examines the impact of CDSS on clinical practice, highlighting both their potential benefits and their limitations and challenges. We detail the experience of clinical medical professionals in the development of a virtual control center for COVID-19 patients (C3 COVID-19) in Spain during the SARS-CoV-2 pandemic. This tool enabled real-time monitoring of clinical data for hospitalized COVID-19 patients, optimizing personalized and informed medical decision-making. CDSS can offer significant advantages, such as improving the quality of inpatient care, promoting evidence-based clinical and therapeutic decision-making, facilitating treatment personalization, and enhancing healthcare system efficiency and productivity. However, the implementation of CDSS presents challenges, including the need for physicians to become familiar with the systems and software, and the necessity for ongoing updates and technical support of the systems.

临床决策支持系统(CDSS)是一种基于计算机的工具,它利用对大量健康数据的分析,协助医疗保健专业人员做出预防、诊断或治疗方面的临床决策。本综述探讨了 CDSS 对临床实践的影响,强调了 CDSS 的潜在优势及其局限性和挑战。我们详细介绍了在 SARS-CoV-2 大流行期间,临床医疗专业人员在西班牙开发 COVID-19 患者虚拟控制中心(C3 COVID-19)的经验。该工具能够实时监控住院 COVID-19 患者的临床数据,优化个性化和知情的医疗决策。CDSS 具有显著的优势,如提高住院护理质量、促进循证临床和治疗决策、促进个性化治疗以及提高医疗系统的效率和生产力。然而,CDSS 的实施也带来了挑战,包括医生需要熟悉系统和软件,系统需要不断更新和技术支持。
{"title":"Strengths and weaknesses of computerized clinical decision support systems: insights from a digital control center (C3 COVID-19) for early and personalized treatment for COVID-19.","authors":"T F Aiello, C Teijon-Lumbreras, A Gallardo-Pizarro, P Monzó-Gallo, A Martinez-Urrea, G Cuervo, A Del Rio, M Hernández-Meneses, L Morata, J Mensa, A Soriano, C Garcia-Vidal","doi":"10.37201/req/088.2024","DOIUrl":"10.37201/req/088.2024","url":null,"abstract":"<p><p>Clinical Decision Support Systems (CDSS) are computer-based tools that leverage the analysis of large volumes of health data to assist healthcare professionals in making clinical decisions, whether preventive, diagnostic, or therapeutic. This review examines the impact of CDSS on clinical practice, highlighting both their potential benefits and their limitations and challenges. We detail the experience of clinical medical professionals in the development of a virtual control center for COVID-19 patients (C3 COVID-19) in Spain during the SARS-CoV-2 pandemic. This tool enabled real-time monitoring of clinical data for hospitalized COVID-19 patients, optimizing personalized and informed medical decision-making. CDSS can offer significant advantages, such as improving the quality of inpatient care, promoting evidence-based clinical and therapeutic decision-making, facilitating treatment personalization, and enhancing healthcare system efficiency and productivity. However, the implementation of CDSS presents challenges, including the need for physicians to become familiar with the systems and software, and the necessity for ongoing updates and technical support of the systems.</p>","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of anal infection by human papillomavirus in men who have sex with men and its associated clinical and epidemiological factors. 男男性行为者肛门感染人类乳头瘤病毒的流行率及其相关临床和流行病学因素。
Pub Date : 2025-02-01 Epub Date: 2024-11-25 DOI: 10.37201/req/085.2024
M J Munoz-Davila, C Candel-Perez, E García Villalba, M A Muñoz Pérez
{"title":"Prevalence of anal infection by human papillomavirus in men who have sex with men and its associated clinical and epidemiological factors.","authors":"M J Munoz-Davila, C Candel-Perez, E García Villalba, M A Muñoz Pérez","doi":"10.37201/req/085.2024","DOIUrl":"10.37201/req/085.2024","url":null,"abstract":"","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"70-71"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142712272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1